Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections

about

Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

P2860

Q38193337-21B51A0B-7CCF-495E-9765-3235EB5FC01F

P2860

Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections

Item

http://www.wikidata.org/entity/Q39701953

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Caspofungin for the treatment ...... ith invasive fungal infections

@en

Caspofungin for the treatment ...... th invasive fungal infections.

@nl

type

Item

label

Caspofungin for the treatment ...... ith invasive fungal infections

@en

Caspofungin for the treatment ...... th invasive fungal infections.

@nl

prefLabel

Caspofungin for the treatment ...... ith invasive fungal infections

@en

Caspofungin for the treatment ...... th invasive fungal infections.

@nl

P1476

Caspofungin for the treatment ...... ith invasive fungal infections

@en

P2093

Lydia A Herrera

http://www.w3.org/2001/XMLSchema#string

Nathan P Wiederhold

http://www.w3.org/2001/XMLSchema#string

P2860

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Glucan synthase complex of Aspergillus fumigatus.

P304

19-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CMPED.S8016

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23641163

http://www.w3.org/2001/XMLSchema#string

P932

3620773

http://www.w3.org/2001/XMLSchema#string

Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections

about

P2860

P2860

Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932